Vaksin mRNA Personal Turunkan Risiko Kekambuhan Melanoma 42 Persen
KesehatanUji klinis Fase 3 INTerpath-001 menunjukkan vaksin mRNA personal Merck dan Moderna menurunkan risiko kekambuhan atau kematian akibat melanoma sebesar 42 persen.
Uji klinis Fase 3 INTerpath-001 menunjukkan vaksin mRNA personal Merck dan Moderna menurunkan risiko kekambuhan atau kematian akibat melanoma sebesar 42 persen.
These cookies are essential for the website to function properly.
These cookies help us understand how visitors interact with the website.
These cookies are used to deliver personalized advertisements.